Utility of Transpapillary Biopsy and Endoscopic Ultrasound-Guided Tissue Acquisition for Comprehensive Genome Profiling of Unresectable Biliary Tract Cancer
Authors:
- Soma FukudaSFSoma Fukuda
- Susumu HijiokaSusumu Hijioka
- Yoshikuni NagashioYNYoshikuni Nagashio
- Daiki YamashigeDYDaiki Yamashige
- Daiki AgarieDADaiki Agarie
- Yuya HagiwaraYHYuya Hagiwara
- Kohei OkamotoKOKohei Okamoto
- Shin YagiSYShin Yagi
- Yasuhiro KomoriYKYasuhiro Komori
- Masaru KuwadaMKMasaru Kuwada
- Yuta MarukiYMYuta Maruki
- Chigusa MorizaneCMChigusa Morizane
Open Access
Abstract
Tissue sampling in biliary tract cancer (BTC) is generally performed through transpapillary biopsy (TPB) or endoscopic ultrasound-guided tissue acquisition (EUS-TA). For the first time, we compared the suitability of specimens obtained using TPB and EUS-TA to determine the optimal tissue-sampling method for comprehensive genome profiling (CGP) analysis in patients with unresectable BTC (UR-BTC). Pathology precheck criteria for CGP analysis comprised the OncoGuide NCC Oncopanel System (NCCOP) and FoundationOne CDx (F1CDx). Seventy-eight patients with UR-BTC (35 TPB and 43 EUS-TA) were included. The NCCOP analysis suitability achievement rate was higher in EUS-TA specimens than in TPB specimens (34.9% vs. 8.6%, p = 0.007), whereas that of F1CDx was 0% in both groups. EUS-TA was identified as an independent factor that contributed to the suitability of the NCCOP analysis. The suitability of the NCCOP analysis of EUS-TA specimens showed a tendency to be higher for mass lesions (43.8% vs. 9.1%, p = 0.065), especially for target size ≥ 18.5 mm, and lower for perihilar cholangiocarcinoma (0% vs. 41.7%, p = 0.077). In TPB, papillary-type lesions (66.7% vs. 3.2%, p = 0.016) and peroral cholangioscopy-assisted biopsies (50.0% vs. 3.3%, p = 0.029) showed better potential for successful NCCOP analysis. EUS-TA is suitable for NCCOP analysis in UR-BTC and may be partially complemented by TPB.Keywords
Funding Information
- the National Cancer Center Research and Development Fund (2022-A-16)
This publication has 41 references indexed in Scilit:
- Prospective registration study of diagnostic yield and sample size in forceps biopsy using a novel device under digital cholangioscopy guidance with macroscopic on‐site evaluationJournal of Hepato-Biliary-Pancreatic Sciences, 2022
- The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancerAnnals of Oncology, 2022
- ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working GroupAnnals of Oncology, 2022
- Brush Cytology, Forceps Biopsy, or Endoscopic Ultrasound-Guided Sampling for Diagnosis of Bile Duct Cancer: A Meta-AnalysisDigestive Diseases and Sciences, 2021
- Molecular detection and clinicopathological characteristics of advanced/recurrent biliary tract carcinomas harboring the FGFR2 rearrangements: a prospective observational study (PRELUDE Study)Journal of Gastroenterology, 2020
- Precision medicine for patients with advanced biliary tract cancers: An effective strategy within the prospective MOSCATO-01 trialEuropean Journal of Cancer, 2017
- Clinical next‐generation sequencing successfully applied to fine‐needle aspirations of pulmonary and pancreatic neoplasmsCancer Cytopathology, 2013
- Diagnostic yield of endoscopic retrograde cholangiography and of EUS‐guided fine needle aspiration sampling in gallbladder carcinomasJournal of Hepato-Biliary-Pancreatic Sciences, 2011
- Role of EUS for preoperative evaluation of cholangiocarcinoma: a large single-center experienceGastrointestinal Endoscopy, 2011
- A lexicon for endoscopic adverse events: report of an ASGE workshopGastrointestinal Endoscopy, 2010